Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
Authors' conclusion
Tirzepatide demonstrated superior reductions in HbA1c versus insulin glargine in an Asia-Pacific, predominately Chinese, population with T2D and was generally well tolerated.
Study context
- Population
- Insulin-naive adults (≥18 years) with T2D uncontrolled on metformin (± SU), 66 hospitals in China, South Korea, Australia and India763 (83.2%) in China
- Participants
- 917 adults
- Comparison
- Weekly tirzepatide 5, 10 or 15 mg vs daily insulin glargine
- Tirzepatide 5 mgn = 230
- Tirzepatide 10 mgn = 228
- Tirzepatide 15 mgn = 229
- Insulin glarginen = 230reference
- Primary endpoint
- Non-inferiority of mean change in HbA1c from baseline with tirzepatide 10 mg and 15 mg
- Follow-up
- Week 40
Methodological detailsphase 3, open-label, non-inferiority, multicentre
- Phase 3
- Open-label
- Non-inferiority
- Multicentre
Primary result
As reported in the abstract
Least squares mean (SE) change in HbA1c · baseline to week 40
Tirzepatide 5 mg
−2.24
least squares mean · SE 0.07 · %
Tirzepatide 10 mg
−2.44
least squares mean · SE 0.07 · %
Tirzepatide 15 mg
−2.49
least squares mean · SE 0.07 · %
Insulin glargine
−0.95
least squares mean · SE 0.07 · %
Secondary outcomes
HbA1c < 7.0% · week 40
| Outcome | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Insulin glargine |
|---|---|---|---|---|
| Body weight change · week 40 | −5.0 kg | −7.0 kg | −7.2 kg | 1.5 kg |
| Percent change | −6.5% | −9.3% | −9.4% | +2.1% |
- Hemoglobin A1c (HbA1c) < 7.0% — Each tirzepatide dose vs insulin glargine
- all P < 0.001
- Body weight change — Superior weight reduction, all tirzepatide doses vs insulin glargine
- all P < 0.001
Safety
Adverse events
- Most common AEs with tirzepatide: mild to moderate decreased appetite, diarrhea and nausea
- No severe hypoglycemia was reported
Original publication
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. Published 25 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →